PQA Opioid Measures and Evaluations
Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and what they evaluate during the PQA Annual Meeting in Baltimore, MD.
Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and what they evaluate during the PQA Annual Meeting in Baltimore, MD.
Lisa Hines, PharmD: So, our 3 new measures look at opioid prescribing. So, these are new starts, and it looks at long duration greater than 7 day’s supply, or a high dose, or it looks at initial use of long-acting or extended release opioid. And these are for high plans using administrative claims data. So, these prescribing patterns are important, because they’re correlated with increased risk of downstream, chronic opioid use which can contribute to misuse, and even overdose. So, we consider them a really important way at preventing downstream, long-term use.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025